Benchmark Capital Upgrades CV Therapeutics (CVTX) to Buy Nov 10, 2008 11:41AM

Benchmark Capital upgrades CV Therapeutics (Nasdaq: CVTX) from Hold to Buy. Price target $11.

Benchmark analyst says, "CVTX has been unduly punished for its expense issue going forward. We do not believe ...